Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cord Blood CD19-BCMA CAR-T for Refractory Autoimmune Diseases
NCT06947473Phase 2Recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Mar 2026
- Primary completion
- Jul 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of umbilical cord blood CD19-BCMA CAR-T cells in lupus nephritis (LN), systemic sclerosis (SSc), Sjogren's syndrome and 1 more, sponsored by Beijing Gaobo Hospital. Primary endpoints: Dose-limiting toxicity at 28 days and Adverse events at 30 days. Started Mar 2026; status: recruiting.
02
Drugs
umbilical cord blood CD19-BCMA CAR-T cells
03
Conditions
lupus nephritis (LN)systemic sclerosis (SSc)Sjogren's syndromepulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT06947473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06947473.